Immuron Ltd.
(NASDAQ : IMRN)

( )
IMRN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
0.97%206.001.3%$773.44m
GILDGilead Sciences, Inc.
1.54%64.110.9%$388.34m
CELGCelgene Corporation
0.51%95.221.3%$348.72m
BIIBBiogen Inc.
1.74%235.721.3%$309.32m
ILMNIllumina, Inc.
0.87%288.653.5%$303.84m
VRTXVertex Pharmaceuticals Incorporated
1.16%187.091.9%$267.03m
ALXNAlexion Pharmaceuticals, Inc.
1.65%112.682.0%$250.97m
EXASExact Sciences Corporation
-1.39%118.1624.1%$248.01m
REGNRegeneron Pharmaceuticals, Inc.
0.52%298.382.6%$217.05m
AAgilent Technologies, Inc.
0.96%71.761.6%$206.55m
SRPTSarepta Therapeutics, Inc.
-3.71%120.3114.7%$153.85m
INCYIncyte Corporation
1.68%84.522.5%$100.26m
BMRNBioMarin Pharmaceutical Inc.
1.19%77.414.3%$94.71m
GHDXGenomic Health, Inc.
-0.56%74.221.8%$90.42m

Company Profile

Immuron Ltd. engages in the research and development of oral immunotherapy treatments using dairy-derived antibody products for humans. It operates through the following segments: Research and Development; HyperImmune Products; and Corporate. The Research and Development segment involves the R&D projects performed in Australia and Israel. The HyperImmune Products segment comprises of Travelan activities which occur in Australia, New Zealand, Canada, and the United States. The Corporate segment covers company activities. The company was founded on January 13, 1994 and is headquartered in Southbank, Australia.